🧬 The #KRAS gene is one of the most common oncogenic drivers in #GICancers Today, researchers have been expanding their efforts in targeting the gene and its mutations:

✅ In this video, Dr. @benweinbergmd provides an in-depth recap of key #GICancer trials from #ASCO25, including the #MATTERHORN and #BREAKWATER trials. 💬 He highlights the data of each trial and how they impact the treatment landscape in GI oncology:

📺 In a new video interview, @drlauragoff of @VUMCDiscoveries shares how she chooses between #atezolizumab + #bevacizumab and doublet immunotherapy regimens like #durvalumab + #tremelimumab for patients with advanced #hepatocellular carcinoma:

📺Watch our new interview with @skopetz, where he explains how the BREAKWATER trial aligns with the FDA’s Project FrontRunner initiative by using early response rate data to support accelerated approval in BRAF V600E-mutated metastatic #colorectal cancer:

💊#Camrelizumab combined with concurrent #capecitabine and radiotherapy may provide survival outcomes in patients with resectable extrahepatic #cholangiocarcinoma and gallbladder cancer, according to a recent study:

RT @FoxChaseCancer: @NVijayvergiaMD of Fox Chase Cancer Center, recently joined a roundtable discussion on the current and future treatment….

👉 The treatment landscape for #gastroesophageal cancers has shifted since immunotherapy and molecular profiling have become available. ⭐ We recently spoke with Drs. @SKamath_MD and @SunnieSKim about this rapidly changing landscape in upper GI cancers:

🔎 A trial that compared the efficacy of #ramucirumab + #irinotecan against irinotecan monotherapy has found that both treatments provide a similar OS rate for patients with advanced #gastriccancer who experienced progression:

🔬 Findings from the CheckMate 8HW trial have shown that #nivolumab plus #ipilimumab provides better progression-free survival rates as a first-line therapy compared with chemotherapy and nivolumab across all lines:

⏩ In this clip from our new roundtable series, Stacey Cohen, MD of @fredhutch, comments on the @NCCN #CRC guidelines update, which noted that patients with PIK3CA-tumor mutations may benefit from adjuvant #aspirin therapy. 📺 Watch the full video here:

➡️ The treatment landscape for gastroesophageal cancers has shifted away from systemic cytotoxic therapy alone since IO and molecular profiling have become available. 💬 Experts discuss the rapidly changing care environment in upper GI cancers:

💪 A recent phase 3 randomized trial sought to determine if #exercise can improve the primary outcome of disease-free survival patients with resected #ColonCancer who had completed adjuvant #chemotherapy. 📖 Read more about the study's results here:

💭 Christopher Lieu, MD, @CUAnschutz, shares his top liver-directed therapies for #metastatic #ColorectalCancer with liver involvement, including #SurgicalResection and transplant in select patients. 📺 Interested in learning more? Watch the video here:

🔎In the final analysis of the INTRIGUE study, researchers reported on the OS, PFS, and safety of #ripretinib compared with #sunitinib in patients with advanced gastrointestinal stromal tumors:

📺 In this video, Dr. @EricaBarnell discuses the recent inclusion of @GeneoscopyCo's ColoSense in the @NCCN Guidelines for #ColorectalCancer screening. ❗She highlights how the inclusion reduces disparities in #ColorectalCancerScreening, and more:

📝 Recent study findings presented at #ASCO25 suggest that disitamab vedotin-based regimens could offer an effective and potentially #chemotherapy-sparing option for #HER2-expressing #GastricCancers.

❗For the first time in a phase 3 trial, a therapy has shown a statistically significant overall survival benefit in patients with unresectable locally advanced #PancreaticCancer. ➡️ Read more about the results of the #PANOVA3 trial presented at #ASCO25:

➡️ .@DrRonanKelly discusses the first overall survival results from CheckMate 577, which examined the use of adjuvant nivolumab in patients with resected #esophageal or #gastroesophageal junction cancer following neoadjuvant chemoradiotherapy. #ASCO25.

🔎 Hepatic arterial infusion #chemotherapy may be an effective first-line therapy for patients with #hepatocellular carcinoma and may improve prognosis. 👉 Learn more about the study that showed improvements in PFS, OS, and more:

⚙️ @benweinbergmd of @LombardiCancer discusses the development of a novel genomic and transcriptomic model to determine #regorafenib response in patients with metastatic #colorectalcancer: